Efficacy and Safety of Salvage Surgery After Molecular Targeting Drug Treatment for Advanced Lung Cancer

DOI Web Site 4 Citations 18 References Open Access
  • Ishibashi Naoya
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Tabata Toshiharu
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Nonomura Ryo
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Oshima Yutaka
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Sasaki Takanobu
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Mitomo Hideki
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Sugawara Takafumi
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital
  • Sagawa Motoyasu
    Division of Endoscopy, Tohoku Medical and Pharmaceutical University Hospital
  • Kondo Takashi
    Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital

Bibliographic Information

Other Title
  • 進行性肺癌に対する分子標的薬治療後のサルベージ手術の有効性と安全性について

Search this article

Description

<p>Objective. The efficacy and safety of salvage surgery after down-staging following molecular targeting drug therapy were retrospectively evaluated. Methods. We reviewed the medical records of cases in which salvage surgery was performed for residual tumors that were diagnosed as inoperable and which responded to molecular targeting drugs. The records were anonymized, then a database was created and analyzed it. Results. Among 580 lung cancer surgeries performed at our hospital from January 2011 to March 2017, we extracted and analyzed the cases of 8 patients who underwent surgery after initially being classified as inoperable, following a successful response to molecular targeting drugs. There were no serious side effects or perioperative complications during molecular targeting drug therapy. The pathological effect of molecular targeting drug therapy was classified as follows; Ef.1a (n=2), Ef.1b (n=1), Ef.2 (n=4), and Ef.3 (n=1). Four of the 8 patients were alive (2 remained free of disease and 2 were alive with cancer), while 4 patients died of cancer. The median postoperative survival was 53 months (1-87 months). Conclusion. In cases involving patients with unresectable advanced lung cancer, salvage surgery after treatment with molecular targeting drugs was able to achieve relatively good outcomes without fatal complications.</p>

Journal

  • Haigan

    Haigan 59 (5), 463-466, 2019-10-20

    The Japan Lung Cancer Society

Citations (4)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top